Scholarlink

Background <p>The lipid accumulation product (LAP) is a novel marker of adiposity linked to cardiovascular disease (CVD) risk. This study investigates the relationship between LAP and various cardiovascular outcomes, considering the influence of sleep parameters such as the apnea–hypopnea index (AHI) and oxygen saturation, in a large cohort from the Sleep Heart Health Study (SHHS).</p> Methods <p>We analyzed data from 5,100 participants, examining baseline characteristics, sleep parameters, and metabolic profiles. Cox regression models assessed the association between LAP and incident cardiovascular events over an average follow-up of 11.7&#xa0;years. Kaplan–Meier methods evaluated event-free survival across LAP quartiles.</p> Results <p>Higher LAP quartiles were significantly associated with an increased AHI and a noteworthy decrease in oxygen saturation levels. The incidence of composite CVD events rose from 19.09% in quartile 1 (Q1) to 27.82% in quartile 4 (Q4) (P &lt; 0.001). In univariate Cox regression, the highest LAP quartile was associated with elevated risks of myocardial infarction, stroke, and congestive heart failure. In multivariable models, compared with Q1, participants in Q4 had increased risks of cardiovascular death (hazard ratio [HR] = 1.54, 95% confidence interval [CI]: 1.01–2.35), myocardial infarction/procedures (HR = 1.39, 95% CI 1.03–1.88), and coronary artery bypass grafting (HR = 1.89, 95% CI 1.05–3.40). Kaplan–Meier analyses further demonstrated significantly lower event-free survival in higher LAP quartiles for several cardiovascular outcomes.</p> Conclusion <p>LAP emerges as a significant marker of cardiovascular risk, found to be closely associated with the severity of sleep-disordered breathing and various measures of hypoxia. Monitoring LAP levels and sleep parameters can identify individuals at higher risk for cardiovascular events, particularly those with obstructive sleep apnea, aiding targeted prevention.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of the lipid accumulation product with cardiovascular risk and obstructive sleep apnea: a community-based cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月21日

查看全文
  • Jinhe Cui,
  • Xiaoli Wang,
  • Ningfang Lian,
  • Menglan Chen,
  • Jianming Zhao,
  • Guohuan Chen,
  • Jiefeng Huang

摘要

Background

The lipid accumulation product (LAP) is a novel marker of adiposity linked to cardiovascular disease (CVD) risk. This study investigates the relationship between LAP and various cardiovascular outcomes, considering the influence of sleep parameters such as the apnea–hypopnea index (AHI) and oxygen saturation, in a large cohort from the Sleep Heart Health Study (SHHS).

Methods

We analyzed data from 5,100 participants, examining baseline characteristics, sleep parameters, and metabolic profiles. Cox regression models assessed the association between LAP and incident cardiovascular events over an average follow-up of 11.7 years. Kaplan–Meier methods evaluated event-free survival across LAP quartiles.

Results

Higher LAP quartiles were significantly associated with an increased AHI and a noteworthy decrease in oxygen saturation levels. The incidence of composite CVD events rose from 19.09% in quartile 1 (Q1) to 27.82% in quartile 4 (Q4) (P < 0.001). In univariate Cox regression, the highest LAP quartile was associated with elevated risks of myocardial infarction, stroke, and congestive heart failure. In multivariable models, compared with Q1, participants in Q4 had increased risks of cardiovascular death (hazard ratio [HR] = 1.54, 95% confidence interval [CI]: 1.01–2.35), myocardial infarction/procedures (HR = 1.39, 95% CI 1.03–1.88), and coronary artery bypass grafting (HR = 1.89, 95% CI 1.05–3.40). Kaplan–Meier analyses further demonstrated significantly lower event-free survival in higher LAP quartiles for several cardiovascular outcomes.

Conclusion

LAP emerges as a significant marker of cardiovascular risk, found to be closely associated with the severity of sleep-disordered breathing and various measures of hypoxia. Monitoring LAP levels and sleep parameters can identify individuals at higher risk for cardiovascular events, particularly those with obstructive sleep apnea, aiding targeted prevention.